Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 186 participants.
Also called NCT05213104
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 186 participants
- Registry
-
NCT05213104 -
2021-002608-10
-
- Other papers using this trial's data
- Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05213104. Randomized; single masking; primary purpose treatment. Start 2022-03-23 (actual); primary completion 2024-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
- Acronym
- AFLOAT
- Condition
- Patent Foramen Ovale
- Condition
- Atrial Arrhythmia
- Condition
- Cryptogenic Stroke
- Intervention (Drug)
- Flecainide
- Intervention (Drug)
- Flecainide
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Fonds de Dotation ACTION
Record details
- Record id
cardio:ct-nct05213104- Content hash
389140af8a07de0201a6503675083bbb6c8a442d689a90c21e05cb92445efcda